Aristotle University of Thessaloniki, Medical School, Metabolic Diseases Unit, Second Department of Internal Medicine, Greece.
Expert Opin Investig Drugs. 2010 Dec;19(12):1545-56. doi: 10.1517/13543784.2010.532123. Epub 2010 Nov 4.
The sodium/hydrogen exchanger-1 (NHE-1/SLC9A1) is a ubiquitous plasma membrane protein whose main role is maintenance of intracellular pH and volume. NHE-1 plays a role in atherogenesis; however, its clinical relevance has not yet been established.
We herein review the contribution of NHE-1 in atherogenesis (namely its effect on endothelial cells, monocytes, smooth muscle cells and platelets).
Studies have shown that NHE is involved in atherogenesis-related properties of isolated monocytes. We also consider the relationship between NHE-1 and vascular risk factors such as obesity, diabetes mellitus, hypertension, dyslipidemia and inflammation.
Even though clinical trials with certain NHE-1 inhibitors have had discouraging results, NHE-1 cannot be excluded as a potential future therapeutic target for the prevention and/or treatment of atherosclerosis.
钠/氢交换器-1（NHE-1/SLC9A1）是一种普遍存在的质膜蛋白，其主要作用是维持细胞内 pH 值和体积。NHE-1 在动脉粥样硬化的发病机制中起作用；然而，其临床相关性尚未确定。
我们在此回顾了 NHE-1 在动脉粥样硬化发病机制中的作用（即其对内皮细胞、单核细胞、平滑肌细胞和血小板的影响）。
研究表明，NHE 参与了分离的单核细胞与动脉粥样硬化发病机制相关的特性。我们还考虑了 NHE-1 与肥胖症、糖尿病、高血压、血脂异常和炎症等血管危险因素之间的关系。
尽管某些 NHE-1 抑制剂的临床试验结果令人沮丧，但不能排除 NHE-1 作为预防和/或治疗动脉粥样硬化的潜在未来治疗靶点的可能性。
